Skip navigation

Signatera™
for Skin Cancers

Personalized circulating tumor DNA (ctDNA) testing to inform the management of skin cancers.

Identify Treatment Response and Recurrence Early

Validation and Evidence

Monitor Immunotherapy Response

Assess treatment effectiveness using serial monitoring in patients with skin cancers

6 weeks

identify response to immune checkpoint inhibitor treatment earlier1

Quality and Accuracy

Determine Prognosis

Evaluate risk & detect recurrence earlier in patients with Merkel cell carcinoma

57%

risk of recurrence within 60 days of a positive Signatera™ test2

Get Started

Monitor Treatment Response in Skin Cancers

Understanding if immunotherapy is working can be a clinical challenge

The Signatera™ Residual Disease Test can help assess treatment effectiveness, clarify indeterminate imaging, and identify exceptional responders to help you make the most informed decisions for your patients with skin cancer.1,2

  • Explore the Skin Cancer Data

  • Recurrence Monitoring
    Recurrence Monitoring
    • Assess prognosis and detect recurrence earlier in patients with Merkel cell carcinoma using serial ctDNA testing.2
  • Treatment Monitoring

Provide Confidence for Patients With Skin Cancer

After Jeffrey started dual immunotherapy for his metastatic melanoma, Signatera™ showed a dramatic drop in his ctDNA levels and helped provide assurance that his treatment was working.

Watch Jeffrey’s story to learn how his oncology team used Signatera™ to help guide his care and restore his confidence in his future.

Read the Published Data

INSPIRE Study

Read how Signatera™ combined with standard imaging can predict immunotherapy response as early as 6 weeks into treatment.1

Cutaneous Melanoma

Review data demonstrating that ctDNA status is associated with risk of relapse in patients with stage III melanoma.3

Merkel Cell Carcinoma

Learn how Signatera™ can be used as a predictive biomarker regardless of MCPyV status.2

Personalize the Skin Cancer Treatment Journey

Partner with Natera to get comprehensive and streamlined genomic testing results to support individualized care.

Signatera™ Highly sensitive and personalized tumor-informed test for molecular residual disease (MRD) detection
Altera™ Comprehensive tissue-based genomic profiling for clinically relevant somatic mutations/biomarkers (eg BRAF, CDKN2A, NRAS, TMB) with no additional sample when ordered with Signatera
Empower™ Germline genetic test for commonly screened genes in melanoma (eg BRCA1/BRCA2, TP53, CDKN2A, CDK4, BAP1, PTEN, MITF)

Is Signatera™ right for your patients with skin cancer?



References

1Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873-881. https://doi.org/10.1038/s43018-020-0096-5

2Akaike T, et al. Circulating tumor DNA correlates with Merkel cell carcinoma tumor burden and helps early detection of recurrence. ASCO, Chicago, Illinois, June 3-7, 2022.

3Eroglu Z et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Oral presentation presented at Society for Melanoma Research, Virtual Meeting, Oct 28-31, 2021.